ଭାଇଲୋକ୍ସାଜାଇନ

ଭାଇଲୋକ୍ସାଜାଇନ
Clinical data
Trade names	Qelbree, Vivalan, Emovit, others
Synonyms	ICI-58834; SPN-812; SPN-809
AHFS/Drugs.com	monograph
data	US DailyMed: Viloxazine;
Routes of; administration	By mouth
Legal status
Legal status	US: ℞-only ;
Pharmacokinetic data
Protein binding	76–82%
Metabolism	Hydroxylation (CYP2D6), glucuronidation (UGT1A9, UGT2B15)
Metabolites	5-Hydroxyviloxazine glucuronide
Elimination half-life	IR: 2–5 hours; ER: 7.02 ± 4.74 hours
Excretion	Urine (~90%), feces (<1%)
Identifiers
	IUPAC name (RS)-2-[(2-ethoxyphenoxy)methyl]morpholine;
ECHA InfoCard	100.051.148
Chemical and physical data
Formula	C13H19NO3
Molar mass	୨୩୭.୩0 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCOC1=CC=CC=C1OCC1CNCCO1;
	InChI InChI=1S/C13H19NO3/c1-2-15-12-5-3-4-6-13(12)17-10-11-9-14-7-8-16-11/h3-6,11,14H,2,7-10H2,1H3 ; Key:YWPHCCPCQOJSGZ-UHFFFAOYSA-N ;
(verify)

ଭାଇଲୋକ୍ସାଜାଇନ, ଏକ ବେପାର ନାମ କେଲବ୍ରି, ହେଉଛି ଏକ ଔଷଧ ଯାହା ଧ୍ୟାନାଭାବ ଓ ଅତିସକ୍ରିୟତା ବିକାର (ADHD) ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୨] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୨] ଏହା ପ୍ରାୟ ୩୦ ବର୍ଷ ଧରି ଅବସାଦ ରୋଗ ପାଇଁ ବ୍ୟବହୃତ ହୋଇଥିଲା, ଯାହା ବାଣିଜ୍ୟିକ କାରଣରୁ ବନ୍ଦ ହୋଇଗଲା ।^[୬] ମୂଳ ସୂତ୍ରଟି ତୁରନ୍ତ ବିମୋଚନ ହୋଇଥିବାବେଳେ ଏହା ଏଡିଏଚଡି ପାଇଁ ବିସ୍ତୃତ-ବିମୋଚନ ନିମନ୍ତେ ବ୍ୟବହୃତ ହୋଇଥିଲା ।^[୬]ନ

ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ନିଦ୍ରା ସମସ୍ୟା, ମୁଣ୍ଡବିନ୍ଧା, ନିଦ୍ରାଳୁ, ଥକାପଣ, ଅଇ, ଶୁଖିଲା ପାଟି, କୋଷ୍ଠକାଠିନ୍ୟ, ବିରକ୍ତିଭାବ, ଦୃତ ହୃଦ୍‌ଗତି ହାର ଏବଂ ରକ୍ତଚାପ ବୃଦ୍ଧି ହୋଇପାରେ ।^[୨] କ୍ୱଚିତ୍, ଏହା ଆତ୍ମହତ୍ୟା ଚିନ୍ତାଧାରା କିମ୍ବା ଆଚରଣର କାରଣ ହୋଇପାରେ କିମ୍ବା ଦ୍ୱିପାକ୍ଷିକ ରୋଗୀଙ୍କ ମାନିଆ ହୋଇପାରେ ।^[୨] ଅପବ୍ୟବହାର ହେବାର କମ୍ ଆଶଙ୍କା ଅଛି ।^[୬] ଏହା ଏକ ସିଲେକ୍ଟିଭ୍ ନରଏପିନେଫ୍ରିନ ରିଅପଟେକ୍ ଇନହିବିଟର (NRI) ।^[୨]

ଭାଇଲୋକ୍ସାଜାଇନ ୧୯୬୯ ମସିହାରେ ପେଟେଣ୍ଟ ହୋଇଥିଲା ଏବଂ ୧୯୭୪ରେ ବ୍ରିଟେନରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୬] ^[୭] ଏହି ସମୟରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହା ଅନୁମୋଦିତ ହୋଇନଥିଲା ।^[୮] ଏହାକୁ ୨୦୨୧ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ପୁନଃ ନିର୍ମାଣ କରାଯାଇଥିଲା ଏବଂ ଅନୁମୋଦନ କରାଯାଇଥିଲା ।^[୬] ^[୨] ଏହା ନିୟନ୍ତ୍ରିତ ପଦାର୍ଥ ନୁହେଁ । ^[୯] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଦୈନିକ ୨୦୦ମିଗ୍ରାର ମାତ୍ରା ପାଇଁ ମାସକୁ ପ୍ରାୟ ୩୨୫ ଡଲାର ଖର୍ଚ୍ଚ ହୋଇଥାଏ ।^[୧୦]

ଆଧାର[ସମ୍ପାଦନା]

↑ Swiss Pharmaceutical Society (2000). Swiss Pharmaceutical Society (ed.). Index Nominum 2000: International Drug Directory. Taylor & Francis. pp. 1093–. ISBN 978-3-88763-075-1. Archived from the original on 2022-05-03. Retrieved 2022-10-02.
↑ ^୨.୦୦ ^୨.୦୧ ^୨.୦୨ ^୨.୦୩ ^୨.୦୪ ^୨.୦୫ ^୨.୦୬ ^୨.୦୭ ^୨.୦୮ ^୨.୦୯ ^୨.୧୦ ^୨.୧୧ "Qelbree- viloxazine hydrochloride capsule, extended release". DailyMed. Archived from the original on 28 October 2022. Retrieved 3 May 2022.
↑ Pinder RM, Brogden RN, Speight TM, Avery GS (June 1977). "Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness". Drugs. 13 (6): 401–21. doi:10.2165/00003495-197713060-00001. PMID 324751. S2CID 44804763.
↑ Case DE, Reeves PR (February 1975). "The disposition and metabolism of I.C.I. 58,834 (viloxazine) in humans". Xenobiotica. 5 (2): 113–29. doi:10.3109/00498257509056097. PMID 1154799.
↑ "SID 180462-- PubChem Substance Summary". Archived from the original on 14 June 2013. Retrieved 5 November 2005.
↑ ^୬.୦ ^୬.୧ ^୬.୨ ^୬.୩ ^୬.୪ Findling RL, Candler SA, Nasser AF, Schwabe S, Yu C, Garcia-Olivares J, O'Neal W, Newcorn JH (June 2021). "Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status". CNS Drugs. 35 (6): 643–653. doi:10.1007/s40263-021-00825-w. PMC 8219567. PMID 34003459.
↑ Sneader, Walter (31 October 2005). Drug Discovery: A History (in ଇଂରାଜୀ). John Wiley & Sons. p. 195. ISBN 978-0-470-01552-0. Archived from the original on 30 October 2022. Retrieved 30 October 2022.
↑ Stolerman, Ian (31 July 2010). Encyclopedia of Psychopharmacology (in ଇଂରାଜୀ). Springer Science & Business Media. p. 817. ISBN 978-3-540-68698-9. Archived from the original on 30 October 2022. Retrieved 30 October 2022.
↑ "Viloxazine Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Retrieved 30 October 2022.
↑ "Qelbree". Archived from the original on 30 October 2022. Retrieved 30 October 2022.

[SwissPharmaceuticalSociety2000-1] Swiss Pharmaceutical Society (2000). Swiss Pharmaceutical Society (ed.). Index Nominum 2000: International Drug Directory. Taylor & Francis. pp. 1093–. ISBN 978-3-88763-075-1. Archived from the original on 2022-05-03. Retrieved 2022-10-02.

[PI2022-2] ୨.୦୦ ^୨.୦୧ ^୨.୦୨ ^୨.୦୩ ^୨.୦୪ ^୨.୦୫ ^୨.୦୬ ^୨.୦୭ ^୨.୦୮ ^୨.୦୯ ^୨.୧୦ ^୨.୧୧ "Qelbree- viloxazine hydrochloride capsule, extended release". DailyMed. Archived from the original on 28 October 2022. Retrieved 3 May 2022.

[pmid324751-3] Pinder RM, Brogden RN, Speight TM, Avery GS (June 1977). "Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness". Drugs. 13 (6): 401–21. doi:10.2165/00003495-197713060-00001. PMID 324751. S2CID 44804763.

[renal-4] Case DE, Reeves PR (February 1975). "The disposition and metabolism of I.C.I. 58,834 (viloxazine) in humans". Xenobiotica. 5 (2): 113–29. doi:10.3109/00498257509056097. PMID 1154799.

[iupacformula-5] "SID 180462-- PubChem Substance Summary". Archived from the original on 14 June 2013. Retrieved 5 November 2005.

[Find2021-6] ୬.୦ ^୬.୧ ^୬.୨ ^୬.୩ ^୬.୪ Findling RL, Candler SA, Nasser AF, Schwabe S, Yu C, Garcia-Olivares J, O'Neal W, Newcorn JH (June 2021). "Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status". CNS Drugs. 35 (6): 643–653. doi:10.1007/s40263-021-00825-w. PMC 8219567. PMID 34003459.

[7] Sneader, Walter (31 October 2005). Drug Discovery: A History (in ଇଂରାଜୀ). John Wiley & Sons. p. 195. ISBN 978-0-470-01552-0. Archived from the original on 30 October 2022. Retrieved 30 October 2022.

[8] Stolerman, Ian (31 July 2010). Encyclopedia of Psychopharmacology (in ଇଂରାଜୀ). Springer Science & Business Media. p. 817. ISBN 978-3-540-68698-9. Archived from the original on 30 October 2022. Retrieved 30 October 2022.

[AHFS2022-9] "Viloxazine Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Retrieved 30 October 2022.

[10] "Qelbree". Archived from the original on 30 October 2022. Retrieved 30 October 2022.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]

[୮]

[୯]

[୧୦]